BioMark Diagnostics Inc.
BMKDF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -5.5% | 6.3% | 249.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $1 | $1 | $1 | $0 |
| G&A Expenses | $1 | $1 | $1 | $1 |
| SG&A Expenses | $1 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $1 | $2 | $1 |
| Operating Income | -$2 | -$1 | -$2 | -$1 |
| % Margin | -1,237.3% | -806.1% | -1,128.4% | -3,193.7% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$2 | -$1 | -$2 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2 | -$1 | -$2 | -$1 |
| % Margin | -1,249.7% | -874.5% | -1,200.2% | -3,309.4% |
| EPS | -0.02 | -0.017 | -0.022 | -0.02 |
| % Growth | -19.8% | 25.1% | -10.9% | – |
| EPS Diluted | -0.02 | -0.017 | -0.022 | -0.02 |
| Weighted Avg Shares Out | 91 | 85 | 83 | 72 |
| Weighted Avg Shares Out Dil | 91 | 85 | 83 | 72 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$1 | -$1 | -$1 |
| % Margin | -949.6% | -563.1% | -876.8% | -2,787.4% |